Aniona APS licenses ion channel ataxia program to Ataxion; Later Updates Deal Terms
Danish start-up Aniona APS (drugs targeting ion channels) licensed all rights to its ion channel ataxia program to recently formed Atlas Ventures start-up Ataxion Inc. (orphan neurological disorder therapeutics).
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.